$ELV
Elevance Health, Inc. Stock $elv

$elv Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000115603924000066 Filed on April 18, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$43.89B	$42.58B
YoY Change	0.49%	0.96%
Cost Of Revenue	$4.820B	$3.825B
YoY Change	11.39%	9.88%
Gross Profit	$39.07B	$38.75B
YoY Change	-0.71%	0.16%
Gross Profit Margin	89.02%	91.02%
Selling, General & Admin	$5.066B	$4.886B
YoY Change	5.15%	1.79%
% of Gross Profit	12.97%	12.61%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$0.00	$331.0M
YoY Change	-100.0%	-28.35%
% of Gross Profit	0.0%	0.85%
Operating Expenses	$5.066B	$39.37B
YoY Change	-87.63%	720.27%
Operating Profit	$2.765B	$3.016B
YoY Change	5.21%	6.53%
Interest Expense	$280.0M	-$265.0M
YoY Change	-207.28%	-205.58%
% of Operating Profit	10.13%	-8.79%
Other Income/Expense, Net
YoY Change
Pretax Income	$2.986B	$2.939B
YoY Change	22.33%	12.22%
Income Tax	$685.0M	$690.0M
% Of Pretax Income	22.94%	23.48%
Net Earnings	$2.300B	$2.246B
YoY Change	24.12%	12.92%
Net Earnings / Revenue	5.24%	5.28%
Basic Earnings Per Share	$9.91	$9.65
Diluted Earnings Per Share	$9.85	$9.59
COMMON SHARES
Basic Shares Outstanding	232.4M shares	232.7M shares
Diluted Shares Outstanding	233.4M shares	234.2M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$35.40B	$35.76B
YoY Change	-6.88%	-5.35%
Cash & Equivalents	$6.497B	$6.226B
Short-Term Investments	$28.90B	$29.53B
Other Short-Term Assets	$6.464B	$6.388B
YoY Change	30.96%	29.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$62.27B	$60.95B
YoY Change	4.24%	1.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.450B	$4.451B
YoY Change	-13.63%	0.75%
Goodwill	$25.96B	$25.95B
YoY Change	2.72%	2.67%
Intangibles	$10.45B	$10.71B
YoY Change	-2.39%	-1.88%
Long-Term Investments	$37.15B	$37.63B
YoY Change	5.97%	8.2%
Other Assets	$2.196B	$2.245B
YoY Change	2.95%	20.89%
Total Long-Term Assets	$50.71B	$50.95B
YoY Change	2.61%	3.51%
TOTAL ASSETS
Total Short-Term Assets	$62.27B	$60.95B
Total Long-Term Assets	$50.71B	$50.95B
Total Assets	$113.0B	$111.9B
YoY Change	3.5%	2.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.760B	$5.658B
YoY Change	14.44%	16.11%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$225.0M	$1.575B
YoY Change	-15.09%	494.34%
Long-Term Debt Due	$2.900B	$2.900B
YoY Change
Total Short-Term Liabilities	$41.81B	$10.13B
YoY Change	575.17%	-75.81%
LONG-TERM LIABILITIES
Long-Term Debt	$24.56B	$21.98B
YoY Change	-1.2%	-12.8%
Other Long-Term Liabilities	$1.985B	$12.88B
YoY Change	-81.23%	680.48%
Total Long-Term Liabilities	$26.55B	$34.85B
YoY Change	-25.09%	29.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.81B	$10.13B
Total Long-Term Liabilities	$26.55B	$34.85B
Total Liabilities	$70.69B	$71.29B
YoY Change	-0.38%	-0.41%
SHAREHOLDERS EQUITY
Retained Earnings	$34.58B	$33.09B
YoY Change	9.39%	7.75%
Common Stock	$2.000M	$2.000M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$42.19B	$40.61B
YoY Change
Total Liabilities & Shareholders Equity	$113.0B	$111.9B
YoY Change	3.5%	2.62%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$2.300B	$2.246B
YoY Change	24.12%	12.92%
Depreciation, Depletion And Amortization	$0.00	$331.0M
YoY Change	-100.0%	-28.35%
Cash From Operating Activities	$426.0M	$1.978B
YoY Change	-78.15%	-69.42%
INVESTING ACTIVITIES
Capital Expenditures	$323.0M	$279.0M
YoY Change	-7.71%	-7.31%
Acquisitions		$1.120B
YoY Change		-31.62%
Other Investing Activities	-$495.0M	-$2.031B
YoY Change	53.73%	-7353.57%
Cash From Investing Activities	-$818.0M	-$2.310B
YoY Change	21.73%	-27.45%
FINANCING ACTIVITIES
Cash Dividend Paid	$378.0M	$379.0M
YoY Change	8.0%	7.98%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	668.0M	32.00M
YoY Change	-146.71%	-106.03%
NET CHANGE
Cash From Operating Activities	426.0M	1.978B
Cash From Investing Activities	-818.0M	-2.310B
Cash From Financing Activities	668.0M	32.00M
Net Change In Cash	276.0M	-300.0M
YoY Change	-281.58%	-110.89%
FREE CASH FLOW
Cash From Operating Activities	$426.0M	$1.978B
Capital Expenditures	$323.0M	$279.0M
Free Cash Flow	$103.0M	$1.699B
YoY Change	-93.56%	-72.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Assets Current AssetsCurrent	60029000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	902000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	890000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent	0	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	880000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	876000000	usd
CY2024Q1	us-gaap	Other Long Term Investments OtherLongTermInvestments	6713000000	usd
CY2023Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	6107000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4451000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4359000000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	25947000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	25317000000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10710000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10273000000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2245000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1967000000	usd
CY2024Q1	us-gaap	Assets Assets	111894000000	usd
CY2023Q4	us-gaap	Assets Assets	108928000000	usd
CY2024Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	16459000000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	16111000000	usd
CY2024Q1	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	5298000000	usd
CY2023Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	5600000000	usd
CY2024Q1	us-gaap	Unearned Premiums UnearnedPremiums	1474000000	usd
CY2023Q4	us-gaap	Unearned Premiums UnearnedPremiums	1402000000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5658000000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6910000000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	1575000000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	225000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1649000000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10970000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9894000000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	44334000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41791000000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21976000000	usd
CY2024Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	765000000	usd
CY2023Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	778000000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2201000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1970000000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1908000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1738000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	69523000000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2000000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8883000000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8868000000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	33088000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	31749000000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1365000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1313000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	40608000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	39306000000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	102000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	99000000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	40710000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	39405000000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	111894000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108928000000	usd
CY2024Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	35696000000	usd
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	35868000000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	60948000000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	2900000000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	71184000000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	232544717	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	232544717	shares
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23246000000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	233071088	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	233071088	shares
CY2024Q1	elv	Premiums Earned And Other Operating Revenue PremiumsEarnedAndOtherOperatingRevenue	42273000000	usd
CY2023Q1	elv	Premiums Earned And Other Operating Revenue PremiumsEarnedAndOtherOperatingRevenue	41898000000	usd
CY2024Q1	us-gaap	Net Investment Income NetInvestmentIncome	465000000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	387000000	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-161000000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-113000000	usd
CY2024Q1	us-gaap	Revenues Revenues	42577000000	usd
CY2023Q1	us-gaap	Revenues Revenues	42172000000	usd
CY2024Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	30546000000	usd
CY2023Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	30786000000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3825000000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3481000000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4886000000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4800000000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	265000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	251000000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	235000000	usd
CY2024Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	39638000000	usd
CY2023Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	39553000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2939000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2619000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	690000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	615000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2249000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2004000000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3000000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	15000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	2246000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1989000000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.65
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	8.37
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	9.59
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	8.30
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.63
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.48
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2249000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2004000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-56000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	427000000	usd
CY2024Q1	elv	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	0	usd
CY2023Q1	elv	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	-2000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	2000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	11000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-4000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-2000000	usd
CY2024Q1	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	-2000000	usd
CY2023Q1	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	2000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-52000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	442000000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3000000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	15000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	2000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2194000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2429000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2249000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2004000000	usd
CY2024Q1	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-161000000	usd
CY2023Q1	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-113000000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-27000000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-30000000	usd
CY2024Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	331000000	usd
CY2023Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	462000000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	136000000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-255000000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	62000000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	61000000	usd
CY2024Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	282000000	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	29000000	usd
CY2024Q1	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	29000000	usd
CY2023Q1	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	15000000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1104000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	348000000	usd
CY2024Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	31000000	usd
CY2023Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	306000000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	72000000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3282000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-257000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	18000000	usd
CY2024Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	581000000	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	839000000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-1000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1978000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6469000000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	6103000000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	7443000000	usd
CY2024Q1	elv	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	4898000000	usd
CY2023Q1	elv	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	2489000000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	535000000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	3533000000	usd
CY2024Q1	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	212000000	usd
CY2023Q1	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	-204000000	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1120000000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1638000000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	279000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	301000000	usd
CY2024Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	29000000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	28000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2310000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3184000000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2574000000	usd
CY2024Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1908000000	usd
CY2024Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1350000000	usd
CY2023Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	325000000	usd
CY2024Q1	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	212000000	usd
CY2023Q1	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	-205000000	usd
CY2024Q1	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	-586000000	usd
CY2023Q1	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	-291000000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	566000000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	622000000	usd
CY2024Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	379000000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	351000000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	97000000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	43000000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	100000000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	98000000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	4000000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	2000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-531000000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-300000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2755000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6526000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7387000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6226000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10142000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	39405000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2249000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-52000000	usd
CY2024Q1	elv	Stock Repurchased And Retired During Period Value Including Excise Tax StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax	569000000	usd
CY2024Q1	us-gaap	Dividends Common Stock DividendsCommonStock	382000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	59000000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	40710000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36330000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2004000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	442000000	usd
CY2023Q1	elv	Stock Repurchased And Retired During Period Value Including Excise Tax StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax	626000000	usd
CY2023Q1	us-gaap	Dividends Common Stock DividendsCommonStock	354000000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	342000000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37460000000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	Organization<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving over 46 million medical members through our affiliated health plans as of March 31, 2024. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also to unaffiliated health plans, including pharmacy services, dental, vision and supplemental health insurance benefits, as well as integrated health services. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. In addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum HealthCare, Simply Healthcare and/or Wellpoint. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon Health, Carelon Behavioral Health and CareMore. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have organized our brand portfolio into the following core go-to-market brands:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international business from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation. For additional discussion regarding our segments, including the changes made, see Note 15 “Segment Information” included in this Quarterly Report on Form 10-Q.</span></div>
CY2024Q1	elv	Number Of Medical Members Served NumberOfMedicalMembersServed	46000000	individual
CY2024Q1	elv	Number Of Counties In State Of Kansas Company Does Not Serve NumberOfCountiesInStateOfKansasCompanyDoesNotServe	30	county
CY2024Q1	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	50	state
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2024Q1	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	499000000	usd
CY2023Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	294000000	usd
CY2024Q1	elv	Securities Lending Transactions Initial Collateral Percentage Value SecuritiesLendingTransactionsInitialCollateralPercentageValue	1.02
CY2023Q4	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	212000000	usd
CY2024Q1	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	212000000	usd
CY2024Q1	elv	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	89000000	usd
CY2023Q4	elv	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	87000000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	956000000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	941000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	31329000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	384000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1299000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	4000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	30410000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	31336000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	496000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1338000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	4000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	30490000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	1641	security
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	5855000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	100000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	5972	security
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	12097000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1199000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	1032000000	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	2699000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	55000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	6659000000	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	14842000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1283000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	4000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	4000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	369000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	365000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	6038000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	5900000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	11099000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	10864000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	7648000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	7460000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	6175000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	5821000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	31329000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	30410000000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5401000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5410000000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	511000000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	229000000	usd
CY2024Q1	elv	Investment Gains Losses InvestmentGainsLosses	-166000000	usd
CY2023Q1	elv	Investment Gains Losses InvestmentGainsLosses	-91000000	usd
CY2024Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	294000000	usd
CY2023Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	301000000	usd
CY2024Q1	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	2592000000	usd
CY2023Q4	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	2380000000	usd
CY2023Q4	elv	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.02
CY2024Q1	elv	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.02
CY2024Q1	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	11000000	usd
CY2024Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	6000000	usd
CY2023Q1	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	12000000	usd
CY2023Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	34000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1155000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	30410000000	usd
CY2024Q1	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	2594000000	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	34774000000	usd
CY2024Q1	elv	Percentage Of Total Assets Presented At Fair Value PercentageOfTotalAssetsPresentedAtFairValue	1
CY2024Q1	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	61000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2210000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	30490000000	usd
CY2023Q4	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	2382000000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	35432000000	usd
CY2023Q4	elv	Percentage Of Total Assets Presented At Fair Value PercentageOfTotalAssetsPresentedAtFairValue	1
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	40000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	690000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	615000000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.235
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.235
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	38000000	usd
CY2023Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	543000000	usd
CY2024Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable for the three months ended March 31, 2024 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,751 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods redundancies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods medical claims</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,541 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,484 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,183 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,491 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>
CY2023Q4	elv	Short Duration Contract Liability For Claims Adjustment Expense ShortDurationContractLiabilityForClaimsAdjustmentExpense	15865000000	usd
CY2022Q4	elv	Short Duration Contract Liability For Claims Adjustment Expense ShortDurationContractLiabilityForClaimsAdjustmentExpense	15348000000	usd
CY2023Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	7000000	usd
CY2022Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	6000000	usd
CY2023Q4	elv	Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet	15858000000	usd
CY2022Q4	elv	Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet	15342000000	usd
CY2024Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	30708000000	usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	30751000000	usd
CY2024Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-1205000000	usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-1068000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	29503000000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	29683000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	19580000000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	19948000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	9606000000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	9593000000	usd
CY2024Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	29186000000	usd
CY2023Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	29541000000	usd
CY2024Q1	elv	Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet	16175000000	usd
CY2023Q1	elv	Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet	15484000000	usd
CY2024Q1	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	8000000	usd
CY2023Q1	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	7000000	usd
CY2024Q1	elv	Short Duration Contract Liability For Claims Adjustment Expense ShortDurationContractLiabilityForClaimsAdjustmentExpense	16183000000	usd
CY2023Q1	elv	Short Duration Contract Liability For Claims Adjustment Expense ShortDurationContractLiabilityForClaimsAdjustmentExpense	15491000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	29503000000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	29683000000	usd
CY2024Q1	us-gaap	Supplementary Insurance Information Other Operating Expense SupplementaryInsuranceInformationOtherOperatingExpense	1043000000	usd
CY2023Q1	us-gaap	Supplementary Insurance Information Other Operating Expense SupplementaryInsuranceInformationOtherOperatingExpense	1103000000	usd
CY2024Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	30546000000	usd
CY2023Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	30786000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	16175000000	usd
CY2024Q1	elv	Liability For Claims And Claims Adjustment Expense Ceded Medical Claims Payable LiabilityForClaimsAndClaimsAdjustmentExpenseCededMedicalClaimsPayable	8000000	usd
CY2024Q1	elv	Liability For Claims And Claims Adjustment Expense Other Insurance Lines LiabilityForClaimsAndClaimsAdjustmentExpenseOtherInsuranceLines	276000000	usd
CY2024Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	16459000000	usd
CY2022Q3	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	506000000	usd
CY2022Q3	elv	Number Of Notices Of Appeal NumberOfNoticesOfAppeal	4	appeal
CY2024Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	1.63
CY2024Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	379000000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	1.48
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	351000000	usd
CY2023Q1	elv	Increase In Stock Repurchase Program Authorization IncreaseInStockRepurchaseProgramAuthorization	5000000000	usd
CY2024Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	1100000	shares
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	1300000	shares
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	492.76
CY2023Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	476.66
CY2024Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	566000000	usd
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	622000000	usd
CY2024Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	3633000000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	6254000000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3000000.0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	327.14
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	500000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	499.11
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	300000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	288.95
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	431.01
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3200000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	356.58
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M8D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	521000000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2200000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	297.24
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M23D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	482000000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1100000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	423.94
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	600000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	499.00
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	600000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	352.33
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	456.61
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1100000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	475.31
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0428
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0395
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2800
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2900
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00327
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00316
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y4M24D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y4M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	134.53
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	127.14
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	499.00
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	469.31
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	15000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-106000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-52000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	442000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	2000000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	232700000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	237500000	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1500000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2200000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	234200000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	239700000	shares
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2024Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	35696000000	usd
CY2024Q1	elv	Premiums Earned And Other Operating Revenue PremiumsEarnedAndOtherOperatingRevenue	42273000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3016000000	usd
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	35868000000	usd
CY2023Q1	elv	Premiums Earned And Other Operating Revenue PremiumsEarnedAndOtherOperatingRevenue	41898000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2831000000	usd
CY2024Q1	elv	Operating Revenue OperatingRevenue	42273000000	usd
CY2023Q1	elv	Operating Revenue OperatingRevenue	41898000000	usd
CY2024Q1	us-gaap	Net Investment Income NetInvestmentIncome	465000000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	387000000	usd
CY2024Q1	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-161000000	usd
CY2023Q1	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-113000000	usd
CY2024Q1	us-gaap	Revenues Revenues	42577000000	usd
CY2023Q1	us-gaap	Revenues Revenues	42172000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2939000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2619000000	usd
CY2024Q1	us-gaap	Net Investment Income NetInvestmentIncome	465000000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	387000000	usd
CY2024Q1	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-161000000	usd
CY2023Q1	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-113000000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	265000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	251000000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	235000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3016000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2831000000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001156039-24-000066-index-headers.html	Edgar Link	pending
0001156039-24-000066-index.html	Edgar Link	pending
0001156039-24-000066.txt	Edgar Link	pending
0001156039-24-000066-xbrl.zip	Edgar Link	pending
elv-20240331.htm	Edgar Link	pending
elv-20240331.xsd	Edgar Link	pending
elv-20240331_g1.jpg	Edgar Link	pending
exhibit102poptionagreement.htm	Edgar Link	pending
exhibit102qrsuagreement.htm	Edgar Link	pending
exhibit102rpsuagreement.htm	Edgar Link	pending
exhibit104executiveagreeme.htm	Edgar Link	pending
exhibit311-20240331q12024.htm	Edgar Link	pending
exhibit312-20240331q12024.htm	Edgar Link	pending
exhibit321-20240331q12024.htm	Edgar Link	pending
exhibit322-20240331q12024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
elv-20240331_def.xml	Edgar Link	unprocessable
elv-20240331_lab.xml	Edgar Link	unprocessable
elv-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
elv-20240331_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
elv-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELV
Elevance Health, Inc. Stock $elv

2024 Q2 Form 10-Q Financial Statement

#000115603924000066 Filed on April 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV Elevance Health, Inc. Stock $elv

2024 Q2 Form 10-Q Financial Statement

#000115603924000066 Filed on April 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV
Elevance Health, Inc. Stock $elv